Schear Investment Advisers’s AbbVie ABBV Stock Holding History

Schear Investment Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310K	Buy	1,231 +144	+13%	+$31K	0.1%	75
2026 Q1	$236K	Hold	1,087	–	–	0.1%	73
2025 Q4	$248K	Sell	1,087 -34	-3%	-$7.75K	0.11%	73
2025 Q3	$260K	Hold	1,121	–	–	0.12%	82
2025 Q2	$208K	Sell	1,121 -175	-14%	-$32.5K	0.1%	84
2025 Q1	$272K	Sell	1,296 -15	-1%	-$2.92K	0.16%	82
2024 Q4	$233K	Sell	1,311 -42	-3%	-$7.72K	0.12%	83
2024 Q3	$267K	Buy	+1,353	New	+$253K	0.17%	82
2023 Q4	–	Sell	-8,195	Closed	-$1.22M	–	79
2023 Q3	$1.22M	Sell	8,195 -172	-2%	-$25.3K	1.32%	23
2023 Q2	$1.13M	Buy	8,367 +4	+0%	+$587	1.19%	29
2023 Q1	$1.33M	Buy	8,363 +347	+4%	+$53.1K	1.59%	19
2022 Q4	$1.3M	Buy	+8,016	New	+$1.23M	1.6%	17

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schear Investment Advisers's ABBV Position: Q2 2026 in Review

Schear Investment Advisers increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $31K and bringing the position to 1,231 shares worth $310K. The position accounts for 0.1% of the portfolio, ranked #75.

Schear Investment Advisers first reported a position in ABBV in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.33M in Q1 2023. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Schear Investment Advisers held 1,231 shares of AbbVie worth $310K as of Q2 2026.
Schear Investment Advisers bought 144 AbbVie shares in Q2 2026, an estimated $31K.
AbbVie made up 0.1% of Schear Investment Advisers's portfolio in Q2 2026, its #75 holding.
Schear Investment Advisers first reported a position in AbbVie in Q4 2022 and has held it in 12 quarters since.
Schear Investment Advisers's AbbVie position peaked at $1.33M in Q1 2023.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Schear Investment Advisers's 13F filing for Q2 2026, filed 27 Jul 2026.